In theory, PPAR α/γ dual agonist should be useful for treating major metabolic disorders, such as, hyperglycemia, dyslipidemia and insulin resistance, associated with type 2 diabetes, and for improving complications resulting from aberrant blood glucose and lipid control in metabolic syndrome. The gene discussed is PPARA; the disease is metabolic syndrome.